| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
HNGE
Hinge Health, Inc. Class A
|
Jun 11, 2026 | BUY |
Strong Buy
+7.5% avg upside
17 analysts
|
— | +3.5% |
|
DOCS
Doximity
|
Jun 11, 2026 | BUY |
Buy
+61.4% avg upside
27 analysts
|
— | +3.3% |
|
LFST
Lifestance Health Group
|
Jun 10, 2026 | BUY |
Strong Buy
+8.7% avg upside
14 analysts
|
— | +9.5% |
|
TMDX
TransMedics Group
|
Jun 05, 2026 | BUY |
Strong Buy
+53.4% avg upside
15 analysts
|
— | +13.5% |
|
HCAT
Health Catalyst
|
Jun 04, 2026 | BUY |
Buy
+215.1% avg upside
15 analysts
|
— | · |
|
PHR
Phreesia
|
May 28, 2026 | BUY |
Strong Buy
+82.2% avg upside
21 analysts
|
— | · |
|
WAY
Waystar Holding Corp.
|
May 19, 2026 | BUY |
Strong Buy
+106.0% avg upside
29 analysts
|
— | -6.0% |
|
EVH
Evolent Health
|
May 15, 2026 | BUY |
Strong Buy
+121.1% avg upside
19 analysts
|
— | +6.6% |
|
OPRX
OptimizeRx
|
May 13, 2026 | BUY |
Strong Buy
+158.1% avg upside
9 analysts
|
— | +0.6% |
|
LMRI
Lumexa Imaging Holdings, Inc.
|
May 13, 2026 | BUY |
Strong Buy
+100.8% avg upside
8 analysts
|
— | -3.4% |
|
HSTM
HealthStream
|
May 13, 2026 | BUY |
Buy
+17.0% avg upside
8 analysts
|
— | +0.0% |
|
ASTH
Astrana Health
|
May 07, 2026 | BUY |
Strong Buy
+37.0% avg upside
16 analysts
|
$36.00
8.09% Downside
|
+5.8% |
|
PRVA
Privia Health Group
|
May 07, 2026 | BUY |
Strong Buy
+34.1% avg upside
26 analysts
|
— | -9.8% |
|
AGL
Agilon Health
|
May 06, 2026 | HOLD |
Buy
-59.1% avg upside
26 analysts
|
— | +308.6% |
|
IDXX
Idexx Laboratories
|
May 05, 2026 | BUY |
Buy
+29.2% avg upside
17 analysts
|
— | -0.4% |
|
MD
Pediatrix Medical Group
|
May 05, 2026 | BUY |
Buy
-11.2% avg upside
14 analysts
|
$22.00
6.89% Downside
|
+12.7% |
|
ALHC
Alignment Healthcare
|
Apr 30, 2026 | BUY |
Strong Buy
+1.8% avg upside
19 analysts
|
— | -12.8% |
|
TDOC
Teladoc
|
Apr 29, 2026 | HOLD |
Buy
+257.8% avg upside
37 analysts
|
— | +19.2% |
|
HCSG
Healthcare Services
|
Apr 22, 2026 | BUY |
Buy
+5.8% avg upside
12 analysts
|
— | -10.4% |
|
TALK
Talkspace
|
Mar 09, 2026 | HOLD |
Buy
-13.1% avg upside
12 analysts
|
— | +1.6% |
|
ADUS
Addus Homecare
|
Dec 01, 2025 | BUY |
Strong Buy
+35.9% avg upside
18 analysts
|
— | -22.7% |
|
DH
Definitive Healthcare Corp
|
Nov 07, 2025 | BUY |
Hold
+658.6% avg upside
19 analysts
|
— | -71.1% |
|
INNV
InnovAge Holding
|
Nov 05, 2025 | HOLD |
Sell
-19.2% avg upside
12 analysts
|
— | +78.5% |
|
USPH
US Physical Therapy
|
Nov 05, 2025 | HOLD |
Strong Buy
+44.7% avg upside
12 analysts
|
— | -26.5% |
|
EHC
Encompass Health
|
Nov 03, 2025 | BUY |
Strong Buy
+13.4% avg upside
22 analysts
|
— | -15.3% |
|
PIII
P3 Health Partners
|
Aug 29, 2025 | HOLD |
Buy
+1764.8% avg upside
8 analysts
|
— | +46.8% |
|
AFIB
Acutus Medical
|
Mar 19, 2021 | HOLD |
Sell
+61999900.0% avg upside
5 analysts
|
— | · |
|
EW
Edwards Lifesciences
|
Dec 18, 2018 | BUY |
Strong Buy
+11.7% avg upside
34 analysts
|
— | +51.0% |
|
PODD
Insulet
|
Sep 26, 2018 | BUY |
Strong Buy
+79.3% avg upside
32 analysts
|
— | +55.2% |
|
RMD
Resmed
|
Sep 26, 2018 | BUY |
Buy
+25.4% avg upside
27 analysts
|
— | +18.1% |
|
MDT
Medtronic
|
Sep 26, 2018 | HOLD |
Buy
+23.7% avg upside
38 analysts
|
— | +10.7% |
|
MEDP
Medpace Holdings
|
Aug 17, 2018 | BUY |
Buy
-12.0% avg upside
16 analysts
|
— | +36.6% |
|
THC
Tenet Healthcare
|
Jan 23, 2018 | HOLD |
Strong Buy
+25.2% avg upside
26 analysts
|
— | +15.8% |
|
HCA
HCA Healthcare
|
Jan 23, 2018 | HOLD |
Buy
+14.2% avg upside
35 analysts
|
— | +47.6% |
|
AKTX
Akari Therapeutics
|
Sep 27, 2017 | BUY |
Strong Buy
+957.3% avg upside
7 analysts
|
— | -66.1% |
|
ARWR
Arrowhead Pharmaceuticals
|
Sep 27, 2017 | BUY |
Strong Buy
-19.1% avg upside
26 analysts
|
— | +381.0% |
|
ILMN
Illumina
|
Aug 29, 2017 | BUY |
Buy
-10.0% avg upside
30 analysts
|
— | +79.0% |
|
QDEL
QuidelOrtho
|
Jul 28, 2017 | BUY |
Buy
+185.5% avg upside
13 analysts
|
— | +103.4% |
|
CAH
Cardinal Health
|
May 17, 2017 | HOLD |
Strong Buy
-12.8% avg upside
29 analysts
|
— | -22.0% |
|
TBRG
TruBridge
|
Nov 25, 2015 | HOLD |
Hold
+14.4% avg upside
9 analysts
|
— | -46.5% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.